Mark F. Kubik
Corporate Officer/Principal bij GENOR BIOPHARMA HOLDINGS LIMITED
Profiel
Mark F.
Kubik is currently the Chief Business Officer at Genor Biopharma Holdings Ltd.
He previously worked as the Head of Business Development at Merck & Co., Inc., and as the Chief Business Officer at Actinium Pharmaceuticals, Inc. and OncoImmune, Inc. Kubik received his undergraduate degree from the University of Colorado Boulder and his MBA from The Leeds School of Business.
Actieve functies van Mark F. Kubik
| Bedrijven | Functie | Begin |
|---|---|---|
| GENOR BIOPHARMA HOLDINGS LIMITED | Corporate Officer/Principal | 17-08-2021 |
Eerdere bekende functies van Mark F. Kubik
| Bedrijven | Functie | Einde |
|---|---|---|
OncoImmune, Inc.
 OncoImmune, Inc. Pharmaceuticals: MajorHealth Technology OncoImmune, Inc. engages in the research and development of biopharmaceuticals for the treatment of cancer and autoimmune diseases. It offers CD24Fc, a recombinant fusion protein that targets a novel immune pathway checkpoint; Sialidase Inhibitors, ONC-392, and Echinomycin. The company was founded by Kun-Liang Guan, Ming You, Yang Liu, and Pan Zheng in 2000 and is headquartered in Rockville, MD. | Corporate Officer/Principal | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
| ACTINIUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Opleiding van Mark F. Kubik
| University of Colorado Boulder | Undergraduate Degree |
| The Leeds School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ACTINIUM PHARMACEUTICALS, INC. | Health Technology |
| GENOR BIOPHARMA HOLDINGS LIMITED | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
OncoImmune, Inc.
OncoImmune, Inc. Pharmaceuticals: MajorHealth Technology OncoImmune, Inc. engages in the research and development of biopharmaceuticals for the treatment of cancer and autoimmune diseases. It offers CD24Fc, a recombinant fusion protein that targets a novel immune pathway checkpoint; Sialidase Inhibitors, ONC-392, and Echinomycin. The company was founded by Kun-Liang Guan, Ming You, Yang Liu, and Pan Zheng in 2000 and is headquartered in Rockville, MD. | Health Technology |